TokenPost·
Genmab’s Rina-S Meets Phase 3 Survival Goals in Ovarian Cancer Trial
9.48%
Genmab share gain
The trial showed significant results for both progression-free and overall survival. Genmab plans to discuss next steps with regulators; its shares rose 9.48% at the Oct. 23 close.